long-term efficacy and safety with ibrutinib in cll
Published 7 years ago • 1.1K plays • Length 3:39Download video MP4
Download video MP3
Similar videos
-
3:15
long-term outcomes with ibrutinib
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
1:09
dr. byrd on long-term safety data with ibrutinib in cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:29
the long-term efficacy of acalabrutinib-based regimens in patients with cll
-
14:12
abstract: single-agent ibrutinib 420mg induces durable responses in patients with cll
-
4:40
mcl: long-term safety/efficacy data with ibrutinib
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
1:58
big data on efficacy and toxicity levels for ibrutinib in cll
-
1:22
long-term outcomes and toxicities of ibrutinib in cll
-
12:05
venetoclax combinations, safety and efficacy
-
1:51
long-term results of ibrutinib/umbralisib show efficacy in cll and mcl
-
5:17
ibrutinib, cll, and the elderly
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
2:04
dr. chavez on ongoing efficacy and challenges with ibrutinib in cll